author-photo

Niels Jorgen Ostergaard Skartved

Symphogen

13

Papers

218

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors

2019 Journal of Pharmacokinetics and Pharmacodynamics
Show All
- Source
- Cite
- Save
Citations (1)
Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (27)
Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

2015 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (22)
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

2012 Blood
Show All
- Source
- Cite
- Save
Citations (45)
Abstract 1752: Nonclinical safety and pharmacokinetics of Sym004: A synergistic anti-EGF receptor antibody mixture

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor

2011 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (33)